Longeveron (LGVN) Current Leases (2022 - 2026)
Longeveron's (LGVN) quarterly Current Leases came in at $688000.0 in Q1 2026, up 9.03% year-on-year from $631000.0 in Q1 2025, and up 5.04% quarter-over-quarter from $655000.0 in Q4 2025.
Longeveron (LGVN) Current Leases (2022 - 2026) Analysis & Trends
Longeveron's Current Leases history runs 5 years deep, the most recent figure standing at $688000.0 for Q1 2026.
- On a quarterly basis, Current Leases rose 9.03% year-over-year to $688000.0 in Q1 2026; TTM through Mar 2026 was $688000.0, a 9.03% increase from a year earlier, with the FY2025 full-year figure at $655000.0, up 5.14% from the prior year.
- Current Leases advanced to $688000.0 in Q1 2026 per LGVN's latest filing, from $655000.0 in the prior quarter.
- Across five years, Current Leases topped out at $688000.0 in Q1 2026 and bottomed at $564000.0 in Q4 2022.
- The 5-year median for Current Leases is $623000.0 (2024), against an average of $624090.9.
- Across the five-year window, Current Leases rose 4.99% in 2025 and gained 9.03% in 2026, its largest moves.
- Year by year, Current Leases stood at $564000.0 in 2022, then advanced by 5.14% to $593000.0 in 2023, then advanced by 5.06% to $623000.0 in 2024, then advanced by 5.14% to $655000.0 in 2025, then increased by 5.04% to $688000.0 in 2026.
- Per Business Quant, the three latest LGVN Current Leases figures stand at $688000.0 (Q1 2026), $655000.0 (Q4 2025), and $647000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 531,233.95 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 20.58 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 872,589.03 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 720.00 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 11.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 16.61 Mn |
| 10 | Longeveron | 3.97 Mn | -11.79 Mn | 264,000.00 | 688,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 688,000.00 |
| Dec 31, 2025 | 655,000.00 |
| Sep 30, 2025 | 647,000.00 |
| Jun 30, 2025 | 639,000.00 |
| Mar 31, 2025 | 631,000.00 |
| Dec 31, 2024 | 623,000.00 |
| Sep 30, 2024 | 616,000.00 |
| Jun 30, 2024 | 608,000.00 |
| Mar 31, 2024 | 601,000.00 |
| Dec 31, 2023 | 593,000.00 |
| Dec 31, 2022 | 564,000.00 |